Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Thome covers the Healthcare sector, focusing on stocks such as Alkermes, Jazz Pharmaceuticals ... AnaptysBio (ANAB) Company Description: AnaptysBio, Inc. is a clinical stage biotechnology company, ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) on November 8 and set a price target ...

Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

(RTTNews) - Alkermes plc (ALKS) released a profit for its third quarter that increased from last year but missed the Street estimates. The company's ... those of Nasdaq, Inc. Founded in the ...

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

About Celldex Therapeutics, Inc. and Alkermes plc Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of ...

Myrobalan Therapeutics, a biotechnology company developing novel oral small ... Most recently, she served as Vice President of CNS biology at Alkermes, Inc., where she led preclinical biology ...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...